

ASX Release

Date: 20 March 2026

Section 708A(5)(e) disclosure notice – Issue of Ordinary Shares

Imugene Limited (ASX: IMU) (**Imugene** or **Company**) has issued 35,445,999 fully paid ordinary shares at an issue price of \$0.18 per share pursuant to the placement announced to the ASX on 11 March 2026 and as per the Appendix 2A released today (**Securities**).

Details of the securities issued are as follows:

Class:	Ordinary shares
ASX Code:	IMU
Date of the issue:	20 March 2026
Total number of securities issued:	35,445,999

The Company gives notice pursuant to section 708A(5)(e) of the *Corporations Act 2001* Cth (**Corporations Act**) that:

1. the above securities have been issued without disclosure to investors under part 6D.2 Corporations Act;
2. this notice is given under section 708A(5)(e) of the Corporations Act and in accordance with section 708A(6) of the Corporations Act;
3. at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. sections 674 and 674A of the Corporations Act; and
4. at the date of this notice, there is no information required to be disclosed by the Company which is 'excluded information' (as defined in sections 708A(7) and 708A(8) of the Corporations Act).

End



Release authorised by the Company Secretary of Imugene Limited.

Enquiries

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

General Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
communications@imugene.com

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene's



immuno-oncology therapies may become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

For personal use only